Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010256 · ClinicalTrials.gov registry record
The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
A clinical trial, sponsored by University of Arkansas.
- Terminated
- Registry status
- 4
- Enrollment target
NCT01010256: Clinical Trial study, sponsored by University of Arkansas.
NCT01010256 is a clinical trial that was terminated before completion, run by University of Arkansas. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01010256 was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the level of a specific protein (PTEN) in the cancer cells of chronic myelomonocytic leukemia (CMML) patients. This protein might be involved in the transformation from normal blood cells to leukemia cells. The PTEN protein has not been investigated in CMML specifically but it has been discovered in closely related cancers. If this study demonstrates an abnormality in this protein, future testing will be designed to evaluate the genetic abnormality that resulted in lack of the normal presence of this protein. The goal is that the results of this study will help to develop new drugs and strategies to treat the future patients with CMML by understanding the abnormality of the disease at the cellular and molecular levels. The results of this study can also be utilized by future studies to develop individualized treatment to patients who have abnormal levels of this protein.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-11-01 |
| Est. Completion | 2019-10-03 |
Why NCT01010256 stopped before completion
NCT01010256 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01010256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01010256 about?
NCT01010256 is a clinical study titled "The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia". The purpose of this study is to evaluate the level of a specific protein (PTEN) in the cancer cells of chronic myelomonocytic leukemia (CMML) patients. This protein might be involved in the transformation from normal blood cells to leukemia cells. The PTEN protein has not been investigated in CMML s...
What is the current status of trial NCT01010256?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2009-11-01. Estimated completion is 2019-10-03.
Who is sponsoring clinical trial NCT01010256?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI